Mucopolysaccharidosis type I: founder effect of the p.P533R mutation in North Africa.
Common ancestor
Consanguinity
Haplotypes
Maghrebin populations
Mucopolysaccharidosis type I
P.P533R mutation
Polymorphisms
Journal
BMC genomics
ISSN: 1471-2164
Titre abrégé: BMC Genomics
Pays: England
ID NLM: 100965258
Informations de publication
Date de publication:
09 Oct 2024
09 Oct 2024
Historique:
received:
09
11
2023
accepted:
19
08
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
9
10
2024
Statut:
epublish
Résumé
Mucopolysaccharidosis type I is a lysosomal storage disease resulting from a deficiency in alpha-L-iduronidase (IDUA), which causes the accumulation of partially degraded dermatan sulfate and heparan sulfate. This retrospective study, spanning eight years, analyzed data from 45 MPSI patients. The report aimed to explore the potential origin of the p.P533R mutation in the Maghrebin population by constructing a single-nucleotide polymorphism haplotype around the IDUA gene, in order to propose a molecular proof of a founder effect of the MPSI/p.P533R allele. All of the studied patients were from Libya (2), Mauritania (1) Morocco (21) and Tunisia (21) with first cousins being the most frequent union. The diagnosis of MPSI patients often involves the combination of urinary screening, leukocyte IDUA activity determination, and DNA molecular analysis. In our study, to identify the common p.P533R mutation, we performed both DNA sequencing and tetra-primer ARMS PCR assay. Additionally, Haploview was used to determine the specific haplotype that cosegregates with the p.P533R mutation. Controls were genotyped to ensure that all the SNPs were in Hardy-Weinberg equilibrium. In the present report we confirmed the very strong impact of consanguinity on the incidence of MPSI disease. Furthermore, studied families of mixed ancestry shared common and specific haplotype, which was observed in studied populations, suggesting the presence of a founder effect in the North Africa. The p.P533R missense mutation was identified in each patient originated from Libya, Mauritania, Morocco and Tunisia. Furthermore, these MPSI patients exhibited the same IDUA haplotype. The occurrence of a shared AAGGGTG haplotype, among North African populations may be attributed to substantial historical gene exchange between these groups, likely stemming from migration, inter-ethnic marriage, or other forms of interaction throughout history.
Sections du résumé
BACKGROUND
BACKGROUND
Mucopolysaccharidosis type I is a lysosomal storage disease resulting from a deficiency in alpha-L-iduronidase (IDUA), which causes the accumulation of partially degraded dermatan sulfate and heparan sulfate. This retrospective study, spanning eight years, analyzed data from 45 MPSI patients. The report aimed to explore the potential origin of the p.P533R mutation in the Maghrebin population by constructing a single-nucleotide polymorphism haplotype around the IDUA gene, in order to propose a molecular proof of a founder effect of the MPSI/p.P533R allele.
PATIENTS AND METHODS
METHODS
All of the studied patients were from Libya (2), Mauritania (1) Morocco (21) and Tunisia (21) with first cousins being the most frequent union. The diagnosis of MPSI patients often involves the combination of urinary screening, leukocyte IDUA activity determination, and DNA molecular analysis. In our study, to identify the common p.P533R mutation, we performed both DNA sequencing and tetra-primer ARMS PCR assay. Additionally, Haploview was used to determine the specific haplotype that cosegregates with the p.P533R mutation. Controls were genotyped to ensure that all the SNPs were in Hardy-Weinberg equilibrium.
RESULTS
RESULTS
In the present report we confirmed the very strong impact of consanguinity on the incidence of MPSI disease. Furthermore, studied families of mixed ancestry shared common and specific haplotype, which was observed in studied populations, suggesting the presence of a founder effect in the North Africa.
CONCLUSION
CONCLUSIONS
The p.P533R missense mutation was identified in each patient originated from Libya, Mauritania, Morocco and Tunisia. Furthermore, these MPSI patients exhibited the same IDUA haplotype. The occurrence of a shared AAGGGTG haplotype, among North African populations may be attributed to substantial historical gene exchange between these groups, likely stemming from migration, inter-ethnic marriage, or other forms of interaction throughout history.
Identifiants
pubmed: 39385097
doi: 10.1186/s12864-024-10724-1
pii: 10.1186/s12864-024-10724-1
doi:
Substances chimiques
Iduronidase
EC 3.2.1.76
IDUA protein, human
EC 3.2.1.76
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
948Informations de copyright
© 2024. The Author(s).
Références
Clarke LA, Atherton AM, Burton BK, Day-Salvatore DL, Kaplan P, Leslie ND, Scott CR, Stockton DW, Thomas JA, Muenzer J. Mucopolysaccharidosis type I newborn screening: best practices for diagnosis and management. J Pediatr. 2017;182:363–70.
pubmed: 27939258
doi: 10.1016/j.jpeds.2016.11.036
Hampe CS, Wesley J, Lund TC, Orchard PJ, Polgreen LE, Eisengart JB, McLoon LK, Cureoglu S, Schachern P, McIvor RS. Mucopolysaccharidosis type I: current treatments, limitations, and prospects for improvement. Biomolecules. 2021;11(2):189.
pubmed: 33572941
pmcid: 7911293
doi: 10.3390/biom11020189
Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ. Molecular genetics of muccpolysaccharidosis type I: Diagnostic, clinical, and biological implications. Hum Mutat. 1995;6(4):288–302.
pubmed: 8680403
doi: 10.1002/humu.1380060403
Poletto E, Pasqualim G, Giugliani R, Matte U, Baldo G. Worldwide distribution of common IDUA pathogenic variants. Clin Genet. 2018;94(1):95–102.
pubmed: 29393969
doi: 10.1111/cge.13224
Kubaski F, de Poswar FO, Michelin-Tirelli K, Matte UdS, Horovitz DD, Barth AL, Baldo G, Vairo F, Giugliani R. Mucopolysaccharidosis type I. Diagnostics. 2020;10(3):161.
pubmed: 32188113
pmcid: 7151028
doi: 10.3390/diagnostics10030161
Aldenhoven M, Wynn RF, Orchard PJ, O’Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood, The Journal of the American Society of Hematology. 2015;125(13):2164–72.
Orchard PJ, Gupta AO, Eisengart JB, Polgreen LE, Pollard LM, Braunlin E, Pasquali M, Lund TC. Hematopoietic stem cell transplant for Hurler syndrome: does using bone marrow or umbilical cord blood make a difference? Blood Adv. 2022;6(23):6023–7.
pubmed: 35476057
pmcid: 9699938
doi: 10.1182/bloodadvances.2022007212
Al-Sannaa NA, Bay L, Barbouth DS, Benhayoun Y, Goizet C, Guelbert N, Jones SA, Kyosen SO, Martins AM, Phornphutkul C. Early treatment with laronidase improves clinical outcomes in patients with attenuatedMPSI: a retrospective case series analysis of nine sibships. Orphanet J Rare Dis. 2015;10:1–9.
doi: 10.1186/s13023-015-0344-4
Fecarotta S, Gasperini S, Parenti G. New treatments for the mucopolysaccharidoses: from pathophysiology to therapy. Ital J Pediatr. 2018;44:135–43.
doi: 10.1186/s13052-018-0564-z
Romdhane L, Kefi R, Azaiez H, Halim NB, Dellagi K, Abdelhak S. Founder mutations in Tunisia: implications for diagnosis in North Africa and Middle East. Orphanet J Rare Dis. 2012;7:1–11.
doi: 10.1186/1750-1172-7-52
Lacoste-Dujardin C, Lacoste Y. L’Etat du Maghreb. 1991. Ceres. ISBN : 2–7071–2014–6.
Romdhane L, Abdelhak S, RUOMIOGO. Diseases and collaborators, genetic diseases in the Tunisian population. Am J Med Genet Part A. 2011;155(1):238–67.
doi: 10.1002/ajmg.a.33771
Belmouden A, Melki R, Hamdani M, Zaghloul K, Amraoui A, Nadifi S, Akhayat O, Garchon HJ. A novel frameshift founder mutation in the cytochrome P450 1B1 (CYP1B1) gene is associated with primary congenital glaucoma in Morocco. Clin Genet. 2002;62(4):334–9.
pubmed: 12372064
doi: 10.1034/j.1399-0004.2002.620415.x
Hilal L, Boutayeb S, Serrou A, Refass-Buret L, Shisseh H, Bencherifa F, El Mzibri M, Benazzouz B, Berraho A. Screening of CYP1B1 and MYOC in Moroccan families with primary congenital glaucoma: three novel mutations in CYP1B1. Mol Vis. 2010;16:1215.
pubmed: 20664688
pmcid: 2901188
Kallabi F, Rebeh IB, Felhi R, Sellami D, Masmoudi S, Keskes L, Kamoun H. Molecular analysis of Libyan families with allgrove syndrome: geographic expansion of the ancestral mutation c. 1331+ 1G> A in North Africa. Horm Res Paediatr. 2016;85(1):18–21.
pubmed: 26595337
doi: 10.1159/000441653
Kallabi F, Belghuith N, Aloulou H, Kammoun T, Ghorbel S, Hajji M, Gallas S, Chemli J, Chabchoub I, Azzouz H. Clinical and genetic characterization of 26 Tunisian patients with Allgrove syndrome. Arch Med Res. 2016;47(2):105–10.
pubmed: 27133709
doi: 10.1016/j.arcmed.2016.04.004
Tullio-Pelet A, Salomon R, Hadj-Rabia S, Mugnier C, de Laet M-H, Chaouachi B, Bakiri F, Brottier P, Cattolico L, Penet C. Mutant WD-repeat protein in triple-A syndrome. Nat Genet. 2000;26(3):332–5.
pubmed: 11062474
doi: 10.1038/81642
Belmokhtar KY, Cherkaoui I, Lhousni S, Elidrissi Errahhali M, Elidrissi Errahhali M, Charif M, Boulouiz R, Ouarzane M, Elouali A, Ghanam A, Babakhouya A, Rkain M, Benajiba N, Bellaoui M. Triple-A Syndrome in Morocco: Founder Effect, Age Estimation of the AAAS c.1331+1G>A Variant, and Implications for Genetic Diagnosis. Mol Syndromol. 2024;15(2):96–103.
Cheffi K, Dahbi N, El Khair A, Stambouli H, Elbouri A, Talbi J, Hilali A, El Ossmani H. Consanguinity in the Chaouia population (Morocco): prevalence, trends, determinants, fertility, and spontaneous abortions. Egyptian J Med Hum Genet. 2022;23(1):128.
doi: 10.1186/s43042-022-00337-2
Chkioua L, Khedhiri S, Turkia HB, Chahed H, Ferchichi S, Dridi MFB, Laradi S, Miled A. Hurler disease (mucopolysaccharidosis type IH): clinical features and consanguinity in Tunisian population. Diagnostic Pathol. 2011;6:1–7.
doi: 10.1186/1746-1596-6-113
Alif N, Hess K, Straczek J, Sebbar S, N’Bou A, Nabet P, Dousset B. Mucopolysaccharidosis type I: characterization of a common mutation that causes Hurler syndrome in Moroccan subjects. Ann Human Genet. 1999;63(1):9–16.
doi: 10.1046/j.1469-1809.1999.6310009.x
Matte U, Yogalingam G, Brooks D, Leistner S, Schwartz I, Lima L, Norato DY, Brum JM, Beesley C, Winchester B. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab. 2003;78(1):37–43.
pubmed: 12559846
doi: 10.1016/S1096-7192(02)00200-7
Bie H, Yin J, He X, Kermode AR, Goddard-Borger ED, Withers SG, James MN. Insights into mucopolysaccharidosis I from the structure and action of α-L-iduronidase. Nat Chem Biol. 2013;9(11):739–45.
pubmed: 24036510
pmcid: 4954775
doi: 10.1038/nchembio.1357
Chkioua L, Khedhiri S, Jaidane Z, Ferchichi S, Habib S, Froissart R, Bonnet V, Chaabouni M, Dandana A, Jrad T. La mucopolysaccharidose de type I: identification des mutations du gène alpha-L-iduronidase dans des familles tunisiennes. Arch Pediatr. 2007;14(10):1183–9.
pubmed: 17728118
doi: 10.1016/j.arcped.2007.06.018
Tebani A, Zanoutene-Cheriet L, Adjtoutah Z, Abily-Donval L, Brasse-Lagnel C, Laquerrière A, Marret S, Chalabi Benabdellah A, Bekri S. Clinical and molecular characterization of patients with mucopolysaccharidosis type I in an Algerian series. Int J Mol Sci. 2016;17(5):743.
pubmed: 27196898
pmcid: 4881565
doi: 10.3390/ijms17050743
Chkioua L, Aloui C, Laradi S, Grissa O, Turkia HB, Ouesleti S, Ferchichi S, Miled A, Froissart R. Genetic heterogeneity of 72 patients with Mucopolysaccharidosis in Tunisia. International Journal of New Technology and Research. 2015;1(3): 263696.
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5.
pubmed: 15297300
doi: 10.1093/bioinformatics/bth457
Romdhane L, Mezzi N, Hamdi Y, El-Kamah G, Barakat A, Abdelhak S. Consanguinity and inbreeding in health and disease in North African populations. Annu Rev Genomics Hum Genet. 2019;20:155–79.
pubmed: 31039041
doi: 10.1146/annurev-genom-083118-014954
El Khair A, Dahbi N, Cheffi K, Talbi J, Hilali A, El Ossmani H. Characterization of the Consanguinity in the Moroccan Population of Doukkala. J Soc Sci. 2023;19(1):15–21.
Anwar WA, Khyatti M, Hemminki K. Consanguinity and genetic diseases in North Africa and immigrants to Europe. Eur J Public Health. 2014;24(suppl_1):57–63.
pubmed: 25107999
doi: 10.1093/eurpub/cku104
Halim NB, Alaya Bouafif NB, Romdhane L, Ben Atig RK, Chouchane I, Bouyacoub Y, Arfa I, Cherif W, Nouira S, Talmoudi F. Consanguinity, endogamy, and genetic disorders in Tunisia. J Commun Genet. 2013;4:273–84.
doi: 10.1007/s12687-012-0128-7
M'rad B, Chalbi N. Le choix matrimonial en Tunisie est-il transmissible? Anthropologie. 2004;7:31–7.
Anwar WA, Khyatti M, Hemminki K. Consanguinity and genetic diseases in North Africa and immigrants to Europe. Eur J Public Health. 2014;24(suppl_1):57–63.
pubmed: 25107999
doi: 10.1093/eurpub/cku104
Fareed M, Afzal M. Genetics of consanguinity and inbreeding in health and disease. Ann Hum Biol. 2017;44(2):99–107.
pubmed: 27892699
doi: 10.1080/03014460.2016.1265148
Temaj G, Nuhii N, Sayer J. The impact of consanguinity on human health and disease with an emphasis on rare diseases. Journal of Rare Diseases. 2022;1(1):2.
doi: 10.1007/s44162-022-00004-5
Almazroua AM, Alsughayer L, Ababtain R, Al-Shawi Y, Hagr AA. The association between consanguineous marriage and offspring with congenital hearing loss. Ann Saudi Med. 2020;40(6):456–61.
pubmed: 33307738
pmcid: 7733643
doi: 10.5144/0256-4947.2020.456
Girotto G, Mezzavilla M, Abdulhadi K, Vuckovic D, Vozzi D, Alkowari MK, Gasparini P, Badii R. Consanguinity and hereditary hearing loss in Qatar. Hum Hered. 2014;77(1–4):175–82.
pubmed: 25060281
doi: 10.1159/000360475
Rangel DM, Nóbrega PR, Saraiva-Pereira ML, Jardim LB, Braga-Neto P. A case series of hereditary cerebellar ataxias in a highly consanguineous population from Northeast Brazil. Parkinsonism Relat Disord. 2019;61:193–7.
pubmed: 30389370
doi: 10.1016/j.parkreldis.2018.10.027
Jiao B, Zhou Z, Hu Z, Du J, Liao X, Luo Y, Wang J, Yan X, Jiang H, Tang B. Homozygosity mapping and next generation sequencing for the genetic diagnosis of hereditary ataxia and spastic paraplegia in consanguineous families. Parkinsonism Relat Disord. 2020;80:65–72.
pubmed: 32961396
doi: 10.1016/j.parkreldis.2020.09.013
Scott HS, Litjens T, Nelson PV, Brooks DA, Hopwood JJ, Morris CP. α-L-Iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. Hum Mutat. 1992;1(4):333–9.
pubmed: 1301941
doi: 10.1002/humu.1380010412
Gort L, Chabás A, Coll MJ. Analysis of five mutations in 20 mucopolysaccharidosis type I patients: high prevalence of the W402X mutation. Hum Mutat. 1998;11(4):332.
pubmed: 10215409
doi: 10.1002/(SICI)1098-1004(1998)11:4<332::AID-HUMU16>3.0.CO;2-P
Mediano FR. Iberia, North Africa, and the Mediterranean. In Iberian World 1450-1820. Nueva York: Routledge; 2019. pp. 106–125.
Clancy-Smith J. Mediterraneans: North Africa and Europe in an Age of Migration. Berkeley: California University Press; 2010.
Bouzid F, Sebbar MS, El Mousadik A, Alif N. IDUA gene polymorphisms among mucopolysaccharidosis and healthy Moroccan subjects. Gene Rep. 2020;21:100798.
doi: 10.1016/j.genrep.2020.100798
Chkioua L, Khedhiri S, Kassab A, Bibi A, Ferchichi S, Froissart R, Vianey-Saban C, Laradi S, Miled A. Molecular analysis of mucopolysaccharidosis type I in Tunisia: identification of novel mutation and eight Novel polymorphisms. Diagn Pathol. 2011;6(1):1–8.
Chkioua L, Khedhiri S, Turkia HB, Tcheng R, Froissart R, Chahed H, Ferchichi S, Ben Dridi MF, Vianey-Saban C, Laradi S. Mucopolysaccharidosis type I: molecular characteristics of two novel alpha-L-iduronidase mutations in Tunisian patients. Diagn Pathol. 2011;6:1–6.
Venturi N, Rovelli A, Parini R, Menni F, Brambillasca F, Bertagnolio F, Uziel G, Gatti R, Filocamo M, Donati M. Molecular analysis of 30 mucopolysaccharidosis type I patients: evaluation of the mutational spectrum in Italian population and identification of 13 novel mutations. Hum Mutat. 2002;20(3):231–231.
pubmed: 12203999
doi: 10.1002/humu.9051
Li P, Wood T, Thompson JN. Diversity of mutations and distribution of single nucleotide polymorphic alleles in the human α-l-iduronidase (IDUA) gene. Genet Med. 2002;4(6):420–6.
pubmed: 12509712
doi: 10.1097/00125817-200211000-00004